Key Points The Johns Hopkins Arthritis Center conducted a study to determine the presence of gum disease in patients who have Rheumatoid Arthritis (RA). Oral health exams were performed on patients who have RA and healthy volunteers for comparison. Data was collected from 100 RA patients and 40 healthy volunteers. 70% of the RA patients […]
A recent study by the Johns Hopkins Arthritis Center reveals yoga holds positive results for arthritis sufferers in terms of both mind and body.
RAVE Mobile provides interactive, point-of-care, practice improvement tools for rheumatologists and other clinicians.
Initial combination therapy has been shown to be superior to step-up combination therapy in groups of RA patients; however, these findings are difficult to reconcile with the observation that many RA patients will have complete remission of disease on methotrexate alone. Practice patterns tend to emphasize initial treatment with methotrexate monotherapy, followed by the addition of other agents in combination for those with inadequate responses.
Antibodies against citrullinated proteins have emerged as powerful diagnostic and prognostic tools in RA that may contribute to the initiation phases of the disease. The enzymes that catalyze the citrullination process, known as peptidyl argenine deiminases (or PADs), may also be involved in the initiation and propagation steps of the RA disease process. Additionally, autoimmunity to these catalysts may identify a subset of RA patients with unique disease phenotypes.
The T-cell inhibitor efalizumab (Raptiva) has demonstrated efficacy in the treatment of moderate to severe plaque psoriasis. However, it has not demonstrated efficacy for the treatment of psoriatic arthritis and, in one study, was associated with worsening of arthritis symptoms. Only a minority of individuals with psoriasis have a concomitant inflammatory arthritis, making therapy with efalizumab an option for the treatment of a large number of psoriasis patients who have no articular involvement.
Knuckle Cracking Q&A from Johns Hopkins Arthritis Center
Arthritis News > Continuation For TNF Switch High rates of continuation for RA patients switched to second TNF inhibitor January 2007 – Jon Giles, M.D. Clinical trials of TNF inhibitors in rheumatoid arthritis (RA) typically show minimal clinical response rates (i.e. ACR20) of 60 to 70%. However, clinically meaningful response rates, such as an ACR50 […]
Arthritis News > RA & Subclinical Synovitis RA Patients in Remission May Still Have Subclinical Synovitis January 2007 – Jon Giles, M.D. Radiographic progression has been demonstrated in RA patients with no clinical evidence of synovitis on physical examination. This has raised the question of whether joint damage and destruction can occur in the absence […]
Arthritis News > Genentech Announcement Genentech announces rare opportunistic infection in two Lupus patients treated with Rituximab. John Giles, M.D. Genentech/Biogen Idec, the manufacturers of rituximab (Rituxan), have reported the occurrence of two cases of progressive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the central nervous system (CNS), in two patients receiving the drug […]